Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: Comparison with an anti-CD31 monoclonal antibody

Neuropathology

Volumn 25, Issue 3, 2005, Pages 201-206

  Yao, Yongxue ^a,b   Kubota, Toshihiko ^a   Takeuchi, Hiroaki ^a   Sato, Kazufumi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Anti CD105 mAb; Glioma; Microvessel density; Prognosis

Indexed keywords

ENDOGLIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD105; MONOCLONAL ANTIBODY CD31; MONOCLONAL ANTIBODY ENDOGLIN; UNCLASSIFIED DRUG; VASCULOTROPIN; CD31 ANTIGEN; CELL SURFACE RECEPTOR; DIAGNOSTIC AGENT; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BLOOD VESSEL DIAMETER; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BIOSYNTHESIS; BRAIN TUMOR; COMPARATIVE STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SURVIVAL; SURVIVAL RATE; VASCULARIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD31; ASTROCYTOMA; BRAIN NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27244431905     PISSN: 09196544     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2005.00632.x     Document Type: Article

References (23)

1. Folkman J. Angiogenesis and tumor growth. N Engl J Med 1996; 334: 921.
2. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188.
3. Fox SB, Gatter KC, Harris A. Tumor angiogenesis. J Pathol 1996; 179: 232-237.
4. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996; 77: 362-372.
5. Abdulrauf SI, Edvardsen K, Ho KL, Yang XY, Rock JP, Rosenblum ML. Vascular endothelial growth factor expression and vascular density as prognostic marker of survival in patients with low-grade astrocytoma. J Neurosurg 1998; 88: 513-520.
6. Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H. Prognostic value of vascular endothelial growth factor and its receptors flt-1 and flk-1 in astrocytic tumors. Acta Neurochir 2001; 143: 159-166.
7. Torp SH, Alsaker M. Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol Res Pract 2002; 198: 261-265.
8. Kumar P, Wang JM, Bernabeu C. CD105 and angiogenesis. J Pathol 1996; 178: 363-366.
9. Vermeulen PB, Gasparini G, Fox PB et al. Quantification of angiogenesis in solid human tumors: an international consensus on the methodology and criteria of evaluation. Eur J Cancer 1996; 32A: 2474-2484.
10. Wang JM, Kumar S, Pye D, Haboubi N, Al-Nakib L. Breast carcinoma: comparative study of tumor vasculature using two endothelial cell markers. J Natl Cancer Inst 1994; 86: 386-388.
11. Cheifetz S, Bellon T, Cales C et al. Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-19030.
12. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 2000; 14: 55-64.
13. Li DY, Sorensen LK, Brooke BS et al. Defective angiogenesis in mice lacking endoglin. Science 1999; 284: 1534-1537.
14. Wang JM, Kumar S, Pye D, van Agthoven A, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumors and normal tissues. Int J Cancer 1993; 54: 363-370.
15. Seon BK, Matsuno F, Haruta Y, Kondo M, Bareas M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997; 3: 1031-1044.
16. Kumar S, Ghellal A, Li C et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59: 856-861.
17. Tanaka F, Otake Y, Yanagihara K et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410-3415.
18. Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51: 268-275.
19. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
20. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenic factor in human gliomas in vivo. Nature 1992; 359: 845-848.
21. Folkerth RD. Descriptive analysis and quantification of angiogenesis in human brain tumors. J Neurooncol 2000; 50: 165-172.
22. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002; 86: 1566-1577.
23. Staume O, Akslen LA. Expression of vascular endothelial growth factor, its receptors (Flt-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159: 223-235.